Clinical review of the Resolute®
zotarolimus-eluting stent for the
treatment of coronary artery disease

Drug-eluting stents (DES) offer reduced rates of clinical and angiographic restenosis compared with bare-metal stents in patients with symptomatic coronary artery disease. Despite availability of multiple different DES, concerns remain regarding relative efficacy and long-term safety. A DES that has optimal efficacy that extends to higher risk cases – specifically to maintain low restenosis rates in patients with diabetes and in small vessels or long lesions – yet has minimal safety concerns is the goal. The Resolute®
zotarolimus-eluting stent (R-ZES) is a new generation DES currently approved for use in Europe and awaiting approval in the USA. The R-ZES utilizes a novel biocompatible polymer on a cobalt–chromium stent platform in order to prolong the duration of drug elution and improve efficacy. This review will summarize the clinical data for the R-ZES in detail and discuss results in the context of the current landscape for percutaneous coronary intervention.

KEYWORDS: drug-eluting stents  restenosis  zotarolimus-eluting stent
**Table 1. Drug-eluting stent devices currently available in the USA.**

<table>
<thead>
<tr>
<th>DES</th>
<th>Polymer</th>
<th>Stent platform</th>
<th>Strut thickness (inches)</th>
<th>Available lengths (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZES (Endeavor®)</td>
<td>Phosphorylcholine polymer</td>
<td>Cobalt alloy</td>
<td>0.0026</td>
<td>8, 12, 14, 24 and 30</td>
</tr>
<tr>
<td>EES (Xience V®, XIENCE nano™, PROMUS®)</td>
<td>Fluorinated copolymer (acrylic polymer coating with a fluoropolymer reservoir layer)</td>
<td>Cobalt–chromium alloy</td>
<td>0.0032</td>
<td>8, 12, 15, 18, 23 and 28</td>
</tr>
<tr>
<td>Paclitaxel-eluting stent (Taxus™ Liberté™)</td>
<td>Translute™ triblock copolymer</td>
<td>Stainless steel</td>
<td>0.0038</td>
<td>8, 12, 16, 20, 24, 28, 32 and 38</td>
</tr>
<tr>
<td>Paclitaxel-eluting stent (ION™)</td>
<td>Hydrophobic copolymer of polystyrene and polyisobutylene</td>
<td>Platinum–chromium alloy</td>
<td>0.0032</td>
<td>8, 12, 16, 20, 24, 28, 32 and 38</td>
</tr>
<tr>
<td>SES (Cypher®)</td>
<td>Elastomeric polymer</td>
<td>Stainless steel</td>
<td>0.0055</td>
<td>8, 13, 18, 23, 28 and 33</td>
</tr>
</tbody>
</table>

*No longer marketed.

**DES: Drug-eluting stent; EES: Everolimus-eluting stent; SES: Sirolimus-eluting stent; ZES: Zotarolimus-eluting stent.**

V® EES, Abbott Laboratories, Abbott Park, IL, USA, and PROMUS®, Boston Scientific, MA, USA; Table 1. The new Resolute® ZES (R-ZES; Medtronic Cardiovascular, Inc., Santa Rosa, California) is CE marked in Europe and pending FDA approval in the USA.

As a result of heightened attention to safety and efficacy in broad patient populations, randomized trials to evaluate DES have gradually become more inclusive [13]. In addition, pivotal trials such as those required for FDA approval have begun to allow treatment of smaller vessels and multivessel disease, in order to include more complex patient and lesion subsets. The RESOLUTE clinical trials program discussed here is an example of the current approach to obtain a core set of lesion-specific data, while also examining clinical outcomes in a broad population.

**Overview of market & unmet clinical needs**

It is currently estimated that 70% of stents implanted are DES [12]. Many of these cases fall into a higher risk, complex or off-label category where the efficacy of individual DES is less well-defined. Furthermore, whether stent type affects ST risk is not well understood. It is possible that variation in drug, polymer and stent characteristics could translate into differences in the risk of this rare event. ST risk, particularly late-ST risk, is a factor to be optimized in the development of new DES.

In pooled data from the E-ZES clinical trial program, the cumulative 5-year incidence of definite or probable ST was favorably compared with BMS, while target lesion revascularization (TLR) was significantly lower (7.0 vs 16.5%; adjusted hazard ratio [HR]: 0.42; p < 0.001) [13]. A large, multicenter, prospective trial designed to compare the incidence of clinical events, including ST, in patients receiving an E-ZES or a SES has recently completed enrolment [14]. The study has enrolled a more broadly inclusive population of patients with multivessel disease and acute myocardial infarction (MI) and will provide important long-term safety data. The R-ZES was designed to provide the same efficacy and safety as the E-ZES, with improved efficacy in more complex lesions and patients.

**Introduction to R-ZES device**

**Device description**

The R-ZES was developed with the same anti-proliferative drug (zotarolimus) and platform as the E-ZES that is currently available in the USA, but uses a new biocompatible tripolymer (Biolinx™) to prolong drug elution [15]. The R-ZES Endeavor stent platform is a thin-strut (0.0036”) cobalt–chromium alloy mounted on a low-profile balloon. A new Integrity® stent platform, engineered with a continuous sinusoid geometry (Figure 1). The Integrity platform provides improved flexibility and smoother tracking for reduced vessel trauma. The Integrity platform is currently used in the R-ZES in most European countries and is likely to be used in the USA and Japan once the device receives regulatory approval in those countries. Both R-ZES devices have identical stent dimensions, drug-dose and drug-elution profiles.

**Polymer**

The proprietary BioLinx polymer is a blend of three polymers – a hydrophilic C19 polymer, a water-soluble polyvinyl pyrrolidinone (PVP) and a hydrophobic C10 polymer. Despite the hydrophobic nature of the C10 component, the higher concentration of the outer hydrophilic PVP component makes this an overall hydrophilic
polymer, with biocompatibility proven in preclinical studies [16]. The PVP component promotes the initial drug burst from the stent surface. The C10 hydrophobic polymer allows the slow, controlled elution of the remaining drug. The drug elution characteristics are such that 50% of the zotarolimus in the stent is eluted within the first week after deployment. The remaining drug continues to elute out to 180 days, which may prove more effective in higher restenosis risk lesions [17,18].

Two RESOLUTE substudies have highlighted the low neointimal obstruction associated with the durable tripolymer of the R-ZES [19,20]. Intravascular ultrasound (IVUS) results from the first-in-man RESOLUTE trial, reported a low (3.7%) neointimal obstruction at 9 months in 88 patients [19]. The authors postulated that the substantially longer drug elution time of the R-ZES likely accounts for this result. Optical coherence tomography was used to compare the tissue coverage of the R-ZES and the fluropolymer-coated EES in patients treated at prespecified optical coherence tomography sites in the RESOLUTE All Comers (R-AC) trial [19]. This substudy evaluated 30 R-ZES patients and 28 EES patients with 13-month follow-up. No differences in neointimal hyperplasia volume (R-ZES: 15.9 mm³; EES: 18.7 mm³; \( p = 0.274 \)) or neointimal volume obstruction (R-ZES: 12.5%; EES: 15.0%; \( p = 0.157 \)) were found between the groups. Incomplete stent apposition was low for both stents (R-ZES: 1.8%; EES: 1.4%; \( p = 0.569 \)) and strut coverage was similar at 92.6% for R-ZES and 94.2% for EES [20].

Zotarolimus
Zotarolimus (formerly ABT-578) is a cyto-static analog made by substitution of the native hydroxyl group at position 42 in rapamycin with a tetrazole ring [21]. This drug is highly lipophilic with an octanol–water partition coefficient greater than sirolimus and paclitaxel. This lipophilic nature prevents rapid dissolution of the drug into the circulation and allows slower elution from hydrophobic components of stent polymers, thereby facilitating enhanced drug levels in the arterial wall around the stent. The lipophilicity of zotarolimus also facilitates crossing of the cell membrane to reach the drugs site of action [21,22].

The mechanism of action of zotarolimus is inhibition of proliferation of smooth muscle cells that occurs in response to expansion of stents against the artery wall. This proliferation is initiated by the release of several growth factors, including PDGF isoforms, β-FGF and thrombin [23,24]. Zotarolimus inhibits events that occur downstream of the binding of these growth factors to cell surface receptors. Zotarolimus binds to an intracellular immunophilin, FKBP-12. This complex secondarily binds to mTOR, a key protein kinase which phosphorylates and inactivates proteins associated with translation. This process results in the arrest of the cell cycle in the G₁ phase and secondarily prevents cell proliferation [21]. Research using a porcine coronary artery model of restenosis, confirmed that zotarolimus bound to FKBP-12 inhibited proliferation of smooth muscle cells and endothelial cells, and further demonstrated that neointimal formation at 28 days was significantly inhibited with a ZES [25].

Preclinical studies
Monocyte adhesion studies have shown that the activated monocytes do not adhere to the BioLinx polymer and preclinical studies further support the noninflammatory nature of the tripolymer blend [17,26]. Inflammation scores from porcine studies of the R-ZES show equivalent biocompatibility compared with the E-ZES. Scanning electron microscope studies show endothelialization as soon as 28 days out and by 180 days there is confluent endothelialization [24].
Clinical profile

Overview of RESOLUTE program

The RESOLUTE clinical program consists of the following multicenter, prospective studies: RESOLUTE [15] – a single-arm first-in-human study of 139 patients; R-AC [27] – a randomized, controlled trial comparing R-ZES and EES in a 1:1 randomization; RESOLUTE International (R-Int) [28] – an observational study of 2200 patients with minimal exclusion criteria; and RESOLUTE US (R-US) [29] – an observational trial of 1241 patients compared with historical controls (Table 2). The RESOLUTE trials were designed using similar end point definitions, adjudication processes and data collection procedures, allowing consistent interpretation and comparison of results.

RESOLUTE first-in-human trial

RESOLUTE was a multicenter, prospective, first-in-human study of 139 patients with de novo native coronary lesions with reference vessel diameters ≥2.5 and ≤3.5 mm, and lesion length ≥14 and ≤27 mm [15]. Exclusion criteria included patients with MI within 72 h of PCI, left ventricular ejection fraction <30%, left main or ostial lesions, severe calcification by angiography and bifurcation lesions. The first 30 patients were included in a 4-month quantitative coronary angiography and IVUS follow-up evaluation, and the next 100 patients underwent quantitative coronary angiography and IVUS evaluation at 9 months postprocedure. Patients were prescribed DAPT (aspirin 75-mg daily plus clopidogrel 300-mg loading dose and 75-mg daily thereafter) for 6 months and aspirin to continue indefinitely. The primary and secondary end points of the trial are described in Table 2. The 9-month in-stent late lumen loss was 0.22 ± 0.27 mm and TLR rates were 0.0, 0.8 and 1.5% at 9, 12 and 24 months, respectively. In comparison, the 1-year late lumen loss was 0.18 mm for the Xience V EES at 1 year [30], 0.09 mm for the Cypher SES at 8 months [31], 0.31 for the Taxus paclitaxel-eluting stent at 8 months [31] and 0.61 mm for the E-ZES at 1-year follow-up [32]. There were no definite and probable ST events through 24-month follow-up.

### Table 2. RESOLUTE clinical program.

<table>
<thead>
<tr>
<th>Trial</th>
<th>n</th>
<th>Design</th>
<th>Lesion criteria</th>
<th>Primary end point</th>
<th>Secondary end points</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>RESOLUTE</td>
<td>139</td>
<td>Multicenter, prospective</td>
<td>Single de novo lesion in native coronary artery; length: ≥14 mm and ≤27 mm</td>
<td>In-stent late lumen loss at 9 months</td>
<td>In-segment late lumen loss, binary restenosis and percent volume obstruction by IVUS at 9 months. Clinical end points: MACE, all-cause death, MI, TLR, ST, TVR and TVF</td>
<td>[15]</td>
</tr>
<tr>
<td>R-AC</td>
<td></td>
<td>Multicenter, prospective</td>
<td>At least one coronary lesion with ≥50% stenosis; RVD: 2.25–4.0 mm</td>
<td>Primary non-inferiority end point: 12-month TLF (composite of cardiac death, target vessel MI and ischemia-driven TLR)</td>
<td>Death, MI, any revascularization, ST†. Angiographic end points: in-stent and in-segment percent stenosis, binary restenosis, MLD and late lumen loss</td>
<td>[26]</td>
</tr>
<tr>
<td>R-US</td>
<td>1402</td>
<td>Multicenter, prospective</td>
<td>One or two de novo lesions in native coronary arteries; RVD: 2.25–4.0 mm</td>
<td>TLF (composite of cardiac death, target vessel MI, and ischemia-driven TLR) at 12 months in the main analysis cohort. In-stent late-loss at 8 months in IVUS sub-study. In-segment late-loss at 8 months in 4 mm stent substudy</td>
<td>Overall clinical outcomes at 12 months: TLF, cardiac death, MI, TLR and definite plus probable ST. Angiographic end points: reference vessel diameter, minimum lumen diameter, percent diameter stenosis, binary restenosis and late lumen loss. IVUS end points: late acquired incomplete apposition and percent volume obstruction</td>
<td>[28]</td>
</tr>
<tr>
<td>R-Int</td>
<td>2349</td>
<td>Multicenter, prospective</td>
<td>At least one coronary vessel suitable for stenting; RVD: 2.25–4.0 mm</td>
<td>Composite of cardiac death and target vessel MI at 1 year</td>
<td>Definite and probable ST† at 1 year</td>
<td>[48]</td>
</tr>
<tr>
<td>R-Japan</td>
<td>100</td>
<td>Multicenter, prospective</td>
<td>One or two de novo lesions in native coronary arteries; RVD: 2.25–3.5 mm</td>
<td>In-stent late lumen loss at 8 months</td>
<td>Clinical end points (MACE) at 12 months. Angiographic end points (binary restenosis, MLD, percentage diameter stenosis) at 8 months</td>
<td>[49]</td>
</tr>
</tbody>
</table>

†According to Academic Research Consortium definition.

EES: Everolimus-eluting stent; IVUS: Intravascular ultrasound; MACE: Major adverse cardiac events; MI: Myocardial infarction; MLD: Minimum lumen diameter; R-AC: RESOLUTE All Comers; R-Int: RESOLUTE International; R-Japan: RESOLUTE Japan; R-US: RESOLUTE US; RVD: Reference vessel diameter; R-ZES: Resolute® Zotarolimus-eluting stent; ST: Stent thrombosis; TLF: Target lesion failure, TLR: Target lesion revascularization; TVF: Target vessel failure; TVR: Target vessel revascularization.
follow-up. These results are sustained at 4-year follow-up with a cumulative TLR rate of 2.3% and 0.0% ST [33]. This feasibility study provided the safety and efficacy data for the R-ZES in de novo coronary lesions as the groundwork for subsequent larger studies in a broader patient population.

RESOLUTE All Comers

The R-AC trial randomized 2300 patients in 17 European sites in a 1:1 fashion to the R-ZES and EES, with 13-month planned angiographic follow-up in 230 patients in each arm [27]. Enrolled patients had at least one coronary lesion 2.25–4.0 mm in diameter, with >50% stenosis and minimal exclusion criteria. Approximately two-thirds of the patients were considered to be complex, defined by the following criteria: placement of a stent in a patient with one or more of the following clinical or lesion characteristics: renal insufficiency, ejection fraction of <30%, occurrence of acute MI within the previous 72 h, >1 lesion per vessel, ≥2 vessels with stents, a lesion measuring >27 mm, bifurcation, bypass grafts, in-stent restenosis, unprotected left main artery, lesions with thrombus or total occlusion. DAPT was prescribed for 6 months. The primary non-inferiority end point of target lesion failure (TLF) was met (R-ZES 8.2% vs EES 8.3%, p non-inferiority < 0.001). There were no significant differences in cardiac death, target vessel MI or ischemia-driven TLR (Table 3). These results were consistent across all relevant subgroups, including patients with diabetes mellitus (DM), multivessel disease, bifurcation lesions, long lesions, overlapping stents, left main lesions and bypass graft disease. There was a higher rate of ARC-defined definite or probable ST in the R-ZES patients (1.6 vs 0.7%; p = 0.05) which is primarily accounted for by early events (0–30 days). 1-year definite ST rate was higher in the R-ZES arm (1.2 vs 0.3%; p < 0.05) and the rate of ARC-definite/probable ST at 1 year was 1.6 versus 0.7% in the R-ZES versus EES patients, respectively (rate difference 0.9; 95% CI: 0.0 and 1.8, respectively; p = 0.05). However, this did not translate into increased rates of clinical end points such as cardiac death or target vessel MI at 1-year follow-up.

Prespecified 2-year clinical outcomes of the R-AC trial demonstrated sustained safety and efficacy for the R-ZES and EES [34]. There was no difference in patient-related outcomes (any death, MI or revascularization) or stent-related outcomes (TLF, cardiac death, target vessel MI or ischemia driven TLR). There were three additional very late (between 1 and 2 years follow-up) ST events in each treatment arm, with no associated mortality.

RESOLUTE US

The R-US trial studied 1402 patients with 1- or 2-vessel CAD at 116 centers across the USA [39]. Lesions were suitable for 2.25– to 4.0-mm stents. The study enrolled 1242 patients in the clinical cohort. A subset of this group, with 2.5- to

Table 3. RESOLUTE program clinical outcomes.

<table>
<thead>
<tr>
<th>End point</th>
<th>R-ZES 1-year (n = 1119)</th>
<th>EES 1-year (n = 1126)</th>
<th>R-ZES 2-year (n = 1121)</th>
<th>EES 2-year (n = 1128)</th>
<th>R-ZES 1-year (n = 1376)</th>
<th>R-ZES 1-year (n = 2299)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLF</td>
<td>8.2</td>
<td>8.3</td>
<td>11.2</td>
<td>10.7</td>
<td>4.7</td>
<td>7.0</td>
</tr>
<tr>
<td>Any death</td>
<td>1.6</td>
<td>2.8</td>
<td>3.2</td>
<td>4.0</td>
<td>1.3</td>
<td>2.4</td>
</tr>
<tr>
<td>Cardiac death</td>
<td>1.3</td>
<td>1.7</td>
<td>2.6</td>
<td>2.2</td>
<td>0.7</td>
<td>1.4</td>
</tr>
<tr>
<td>Any target vessel MI</td>
<td>4.2</td>
<td>4.1</td>
<td>4.7</td>
<td>4.5</td>
<td>1.2</td>
<td>3.1</td>
</tr>
<tr>
<td>Q-wave</td>
<td>0.7</td>
<td>0.4</td>
<td>1.0</td>
<td>0.5</td>
<td>0.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Non-Q wave</td>
<td>3.6</td>
<td>3.6</td>
<td>3.8</td>
<td>4.0</td>
<td>1.1</td>
<td>2.6</td>
</tr>
<tr>
<td>Clinically driven TLR</td>
<td>3.9</td>
<td>3.4</td>
<td>5.7</td>
<td>5.1</td>
<td>2.8</td>
<td>3.4</td>
</tr>
<tr>
<td>Clinically driven TVR</td>
<td>4.9</td>
<td>4.8</td>
<td>10.0</td>
<td>9.1</td>
<td>4.6</td>
<td>4.2</td>
</tr>
</tbody>
</table>

ST (ARC definite & probable)

Early (0–30 days)          | 1.2                     | 0.5                  | 1.9                     | 1.0                   | 0.1                     | 0.9                     |
Late (31–365 days)        | 0.6                     | 0.2                  | 0.6                     | 0.2                   | 0.1                     | 0.7                     |
Very late (361–720 days)  | N/A                     | N/A                  | 0.3                     | N/A                   | 0.3                     | N/A                     |

1 All data presented as percentage event rates.
2 All comparisons are nonsignificant except for all ARC definite and probable ST at 1 year (p = 0.05).
3 One patient had a definite event on day 4 and again on day 31.

ARC: Academic Research Consortium; EES: Everolimus-eluting stent; MI: Myocardial infarction; R-AC: RESOLUTE All Comers; R-Int: RESOLUTE International; R-US: RESOLUTE US; R-ZES: Resolute® zotarolimus-eluting stent; ST: Stent thrombosis; TLF: Target lesion failure; TLR: Target lesion revascularization; TVR: Target vessel revascularization.
3.5-mm stents and a single lesion, comprised the main analysis cohort (n = 1001). The remaining 241 patients were treated with a 2.25 mm stent and/or had two lesions treated. A separate angiographic cohort enrolled 160 patients. The main analysis cohort compared R-ZES treatment outcomes with historical controls derived from the ENDEAVOR clinical program (ENDEAVOR II, ENDEAVOR IV, ENDEAVOR PK and ENDEAVOR II Continued Access trials) [35–37]. The patients in the main analysis cohort were more complex (smaller mean reference vessel diameter and more DM) than historical control patients treated with the E-ZES. The primary end point of 12-month rate of TLF for the main analysis cohort was 3.7% compared with 6.5% for E-ZES controls (propensity score adjusted one-sided 95% CI upper limit: -1.3%; \(p_{\text{non-inferiority}} < 0.001\); \(p_{\text{superiority}} = 0.002\). The 12-month rates of cardiac death, MI and TLR in the main analysis cohort were 0.4, 1.3 and 2.0%, respectively. Overall clinical outcomes for patients with 2.25–4.0 mm stents at 12-months are shown in Table 2. The in-stent binary restenosis rate was 9.2% for the R-ZES stent group; this did not translate into an increased rate of clinical events at 12-month follow-up. There were two ST events – an early probable ST and a definite ST after 30 days – both in 2.25 mm stents. The rate of DAPT was 93.3% at 12-months in the R-US trial.

### RESOLUTE International

The R-Int trial enrolled 2349 patients (3147 lesions) from 88 centers [27]. The only requirement for enrollment was the intent to implant at least one R-ZES (2.25–4.0 mm stent diameter). There were no exclusions for complex patient or lesion characteristics and no restriction on the number of lesions treated. DAPT was recommended for 6 months and continuation of DAPT was at physician discretion thereafter. More than two-thirds of the patients met the prespecified off-label or complex criteria (the same complex criteria as used in R-AC). Chronic total occlusions were present in 6.3% of patients, bifurcation in 18.2% of lesions and multivessel treatment was performed in 14% of patients. The rate of DM was 30.5% and 46% of patients had an acute coronary syndrome with 27% presenting with an MI. The composite primary end point of cardiac death and target vessel MI at 1 year was 4.3%. Most of the events (2.9%) occurred before 30 days postprocedure and were more likely to be a periprocedural MI (3.1%) rather than cardiac death (1.4%).

Clinically driven 1-year rates of TLR and TVR were similar to results observed in the R-AC trial (Table 2). ARC-defined definite and probable ST at 1 year was 0.9% with most events occurring early (0.7%) and three events (0.1%) occurring after 30 days.

### RESOLUTE pooled safety

The RESOLUTE clinical program has studied the R-ZES in over 5100 patients, including a large proportion of patients with complex clinical and lesion characteristics. Consistent efficacy was shown across all the clinical trials. However, low frequency events such as ST are more difficult to interpret in individual trials that are underpowered to determine significant differences between stent types. Since the RESOLUTE trials were designed with similar event definitions, adjudication and data management methodology, the data from these trials could be pooled for analysis of rare events [38]. Propensity scores were used to adjust for between-patient variation across comparisons. Safety endpoints analyzed from the R-ZES pooled data set were death, cardiac death, MI, and ST, which were compared with the R-AC trial data for the patients receiving the EES. Safety outcome data for a cohort of patients without complex clinical or lesion characteristics who underwent single lesion treatment, was also compared with data from patients who had undergone PCI with a BMS in the ENDEAVOR II randomized trial. The BMS treated patients were prescribed 3 months of DAPT and all R-ZES patients received 6 months of DAPT.

All safety end points were similar between the R-ZES and EES patients. The cumulative 2-year rate of cardiac death and MI was 5.4% for the R-ZES group and 6.2% for the EES group (adjusted HR for R-ZES vs EES: 0.873; 95% CI: 0.65 and 1.17, respectively; \(p = 0.37\)) [38]. TLR rates were 5.0 and 5.2% for R-ZES and EES, respectively (adjusted HR: 0.985; 95% CI: 0.71 and 1.36, respectively; \(p = 0.93\)). Importantly, the 2-year cumulative ARC-defined definite and probable ST rates were 1.0% for both R-ZES and EES patients (adjusted HR: 1.335; 95% CI: 0.66 and 2.71, respectively; \(p = 0.42\)).

Death, cardiac death and MI were also similar between the R-ZES subset and BMS historical control patients. The 2-year rate of cardiac death and MI was 4.3% for the R-ZES subset and 5.8% for the BMS control group (adjusted HR for R-ZES vs BMS: 0.880; 95% CI: 0.55 and 1.40, respectively; \(p = 0.59\)). 2-year TLR and
ST rates were significantly lower for the R-ZES patients compared with the BMS patients. TLR rates at 2 years were 3.8% for R-ZES and 14.2% for BMS (adjusted HR: 0.194; 95% CI: 0.13 and 0.29, respectively; p = 0.19). The ARC-defined definite and probable ST rates were 0.3% in the R-ZES subset and 1.3% in the BMS patients (adjusted HR: 0.206; 95% CI: 0.06 and 0.71, respectively; p = 0.01).

Angiography & IVUS outcomes
The R-AC trial was powered for non-inferiority testing of 13-month in-stent percent diameter stenosis [26]. The prespecified criterion for non-inferiority of this angiographic end point was met with 21.65 ± 14.42% in the R-ZES group and 19.76 ± 14.64% in the EES group (pnon-inferiority = 0.04). In-stent and in-segment binary restenosis rates were low in both R-ZES and EES groups (Table 4).

A subset of patients within the RESOLUTE first-in-human and R-US trials underwent angiographic and IVUS analysis at 8 or 9 months after stent placement [15,28]. Angiographic end points in the less complex, single-lesion patients enrolled in the first RESOLUTE trial, were 10.13% in-stent diameter stenosis and 1.0% in-stent binary restenosis and 13.64% and 9.2%, respectively, in the R-US trial. There were six cases of late incomplete apposition, defined as failure of the stent to completely appose the vessel wall that was not observed post stent placement (one required TLR), in the first-in-human trial and one case (1.7%) of late incomplete apposition in the R-US trial (Table 4).

RESOLUTE outcomes in high-risk patients
Clinical studies have identified patients at higher risk for restenosis and stent thrombosis. DM, recent acute MI, chronic renal insufficiency, left main coronary artery or ostial disease and chronic total occlusions are known risk factors for poorer outcomes following DES placement, and many of these characteristics are excluded from registration studies. Recent studies have expanded eligibility to include more complex patient and lesion characteristics in order to more fully understand appropriate treatment options for these patients. The R-AC and the R-Int trials both enrolled a high proportion of complex patients and demonstrated encouraging safety and efficacy in higher risk populations.

Table 4. Angiographic and intravascular US outcomes from RESOLUTE trials.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimal lumen diameter (mm)†</td>
<td>R-ZES 13-months</td>
<td>EES 13-months</td>
<td>R-ZES 8-months (n = 153)</td>
</tr>
<tr>
<td>In-stent</td>
<td>2.20 ± 0.62 (n = 183)</td>
<td>2.23 ± 0.59 (n = 177)</td>
<td>2.40 ± 0.78 (n = 177)</td>
</tr>
<tr>
<td>In-segment</td>
<td>2.03 ± 0.61 (n = 183)</td>
<td>2.01 ± 0.56 (n = 177)</td>
<td>2.12 ± 0.70 (n = 177)</td>
</tr>
<tr>
<td>Late lumen loss (mm)†</td>
<td>0.27 ± 0.43 (n = 183)</td>
<td>0.19 ± 0.40 (n = 177)</td>
<td>0.30 ± 0.54 (n = 177)</td>
</tr>
<tr>
<td>Diameter stenosis (% lumen diameter)</td>
<td>In-stent 21.65 ± 14.42 (n = 191)</td>
<td>19.76 ± 14.64 (n = 186)</td>
<td>13.64 ± 22.25 (n = 186)</td>
</tr>
<tr>
<td>In-segment</td>
<td>26.51 ± 14.01 (n = 191)</td>
<td>25.50 ± 15.02 (n = 186)</td>
<td>24.25 ± 18.15 (n = 186)</td>
</tr>
<tr>
<td>Binary restenosis</td>
<td>In-stent (%) 4.2</td>
<td>3.8</td>
<td>9.2</td>
</tr>
<tr>
<td></td>
<td>In-segment (%) 5.2</td>
<td>6.5</td>
<td>9.8</td>
</tr>
<tr>
<td>IVUS</td>
<td>Volume obstruction (%)</td>
<td>ND</td>
<td>5.34 ± 5.97 (n = 63)</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD or %; binary restenosis is defined as ≥50% stenosis in the target lesion or segment.

†Matched-pair angiography in R-AC trial.
‡p = 0.04; all other comparisons in R-AC trial are nonsignificant.
EES: Everolimus-eluting stent; IVUS: Intravascular ultrasound; ND: No data; R-AC: RESOLUTE All Comers; R-FIH: RESOLUTE first-in-human; R-US: RESOLUTE US; R-ZES: Resolute® zotarolimus-eluting stent.
A sub-study of the R-AC trial examined the impact of patient and lesion complexity on outcomes after R-ZES versus EES treatment [39]. The complex subgroup included patients presenting with acute MI within 72 h (43.2%) and patients with left ventricular ejection fraction <30%. The mean SYNTAX score was 16.6 ± 9.4 in the complex R-ZES patients, compared with 11.2 ± 7.9 in the simple R-ZES patients. Approximately a fourth of R-ZES and EES patients in the complex group had at least one bifurcation or at total occlusion. The target vessel was a bypass graft in 3.7% of patients in the complex group. Overall event rates were higher in complex versus non-complex patients (n = 1520) but were similar between the two treatment arms (R-ZES vs EES) with no significant difference in risk between complex and non-complex patients (p = 0.43 for interaction on TLF at 1 year). Additionally, ARC-defined definite plus probable ST was not significantly different between R-ZES and EES in the complex and simple subgroups.

**Diabetes mellitus**

DM is a predictor of poor prognosis in patients with CAD. Multiple studies have shown poor outcomes, with increased rates of in-stent restenosis, repeat revascularization, ST and death in patients with DM undergoing PCI [40-45]. Studies have reported DES TLR rates as high as 18% among patients with DM and as high as 35% in patients who are insulin-dependent [44]. Revascularization rates are even greater in patients undergoing multivessel PCI [45].

Approximately one-third of the patients enrolled in R-US presented with DM and 9.6% were insulin-dependent [28]. This subgroup was included in a prespecified analysis of outcomes in those treated with 2.5- to 3.5-mm R-ZES. The rate of TLF at 12 months was 4.3% (cardiac death: 0.5%; MI: 0.8%; TLR: 3.0%), similar to the overall trial population, confirming the consistent efficacy of R-ZES in this high-risk patient group.

**Bifurcation lesions**

Bifurcations are complex, technically challenging coronary lesions [46]. Appropriate stent selection is an important consideration, yet sufficient clinical data for various DES options are lacking. The R-ZES has recently been investigated in a three-center Italian registry of patients with >70% stenosis at a major bifurcation point, main vessel diameter >2.5 mm and side-branch diameter >2.0 mm. PCI was performed using a provisional T-stenting approach [47]. The primary end point of the study was freedom from major adverse cardiac events at 9 months. The secondary end point was procedural success defined as post-PCI stenosis <20% in the main vessel and thrombolysis in myocardial infarction 3 flow in the main vessel and side-branch. A total of 180 consecutive patients were enrolled – 29% had DM and 62.8% presented with acute coronary syndrome. The target bifurcation was in an unprotected left main artery in 16.7% of patients. The procedural success rate was 98.3% and major adverse cardiac event-free survival at 9 months was 97.8%. No definite, probable or possible stent thromboses occurred during the study.

**How R-ZES fits into the field of medical devices**

As a group of medical devices, DES are an example of what was a breakthrough technology

<table>
<thead>
<tr>
<th>DES</th>
<th>Polymer</th>
<th>Stent platform</th>
<th>Current status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resolute® zotarolimus-eluting stent (Resolute®, Resolute Integrity®)</td>
<td>Biocompatible Biolinx™ tripolymer (hydrophilic C19 polymer, water-soluble PVP and a hydrophobic C10 polymer)</td>
<td>Cobalt–chromium alloy; Integrity uses continuous sinusoidal design</td>
<td>Approved in the EU, pending approval in the USA, Australasia and Japan</td>
</tr>
<tr>
<td>EES (PROMUS Element™)</td>
<td>Biocompatible, fluorinated copolymer (acrylic polymer coating with a fluoropolymer reservoir layer)</td>
<td>Platinum–chromium alloy</td>
<td>Approved in the EU</td>
</tr>
<tr>
<td>Everolimus-eluting bioresorbable vascular scaffold (ABSORB™)</td>
<td>Bioreabsorbable poly(lactic acid)</td>
<td>N/A</td>
<td>Approved in the EU, pending approval in the USA</td>
</tr>
<tr>
<td>Paclitaxel-eluting stent (JACTAX™)</td>
<td>Abluminal biodegradable poly(lactic acid) polymer with microdots of paclitaxel embedded</td>
<td>Stainless steel</td>
<td>Investigational</td>
</tr>
<tr>
<td>Biolimus A9-eluting stent (BioMatrix Flex™, Nobori™)</td>
<td>Abluminal biodegradable poly(lactic acid) polymer</td>
<td>Stainless steel</td>
<td>BioMatrix Flex: CE marked, approved in France; Nobori: approved in Japan</td>
</tr>
</tbody>
</table>

**Table 5. New alternative drug-eluting stent devices.**

**DES**: Drug-eluting stent; **EES**: Everolimus-eluting stent; **PVP**: Polyvinyl pyrrolidinone.
in 2003, becoming a subject of more mature product development and investigation over a rapid time frame during the past decade (Table 5). The interactions between stent design, polymer chemistry and drug-delivery are better understood and allow for more rational selection of these components in the design of new devices. Safety concerns surrounding very late ST with use of DES have lingered and BMS have generally been looked upon as the gold standard for safety. DES have provided the standard for efficacy given the significant reduction in TVR associated with their use. More recent trials have neutralized the safety concerns. For instance, pooled data from the RESOLUTE trials comparing over 6000 patients treated with R-ZES with a contemporary DES (Xience EES) and BMS were recently presented at the 2011 Euro-PCR meeting in France [38]. Clinically driven TVR at 3 years was lower in the DES group. Interestingly, ST rates were lower in the DES group compared with the BMS group. Similar and low rates of target vessel failure and ST were observed for both DES types over a 3-year follow-up. The R-US clinical trial showed a significant reduction in target vessel failure in the R-ZES stent group compared with historical controls of the E-ZES stent, despite inclusion of 2.25 mm lesions and a greater proportion of patients with DM in this study. These recent trials represent a paradigm shift in the perception of DES safety and suggest that DES use in complex is reasonable.

Executive summary

Device description
- The Resolute® zotarolimus-eluting stent (R-ZES) combines the antiproliferative drug, zotarolimus, with a biocompatible tripolymer on a thin-strut cobalt–chromium stent platform.
- Zotarolimus is a cytostatic rapamycin analog that inhibits smooth muscle proliferation and reduces neointimal hyperplasia.
- Zotarolimus concentration is 1.6 µg/mm² stent length.
- A cobalt–chromium alloy is used in the original Endeavor® Resolute stent and the new Resolute Integrity® stent.
- The Integrity bare-metal stent platform is improved by the use of a continuous sinusoïdal design to improve flexibility and tracking.
- The Biolinx™ polymer is a blend of a hydrophilic C19 polymer, water-soluble polyvinyl pyrrolidinone and a hydrophobic C10 polymer.
- The polymer blend provides an initial drug burst followed by slow elution of zotarolimus over 180 days.
- The polymer is biocompatible with a hydrophilic surface.

Clinical outcomes
- Clinically driven target lesion revascularization (TLR) rates in patients with single de novo lesions range from 0.7–2.0% and 3.4–3.9% in more complex patient populations.
- R-ZES target lesion failure (TLF) is noninferior to the everolimus-eluting stent (EES; 8.2 vs 8.3%; p < 0.001).
- No significant differences in cardiac death, target vessel myocardial infarction (MI) or ischemia-driven TLR in RESOLUTE All Comers (R-AC) trial at 1 and 2 years. Results were consistent across all relevant subgroups.
- Low rates of definite and probable stent thrombosis (ST) across trials at 1 year (0.0% RESOLUTE first-in-human; 1.6% R-AC; 0.1% RESOLUTE US [R-US]; 0.9% RESOLUTE International).
- Pooled analysis of adverse events showed similar cumulative incidence of cardiac death or MI (5.4% for R-ZES and 6.2% for EES) and definite or probable ST (1.0% for both R-ZES and EES).

Angiographic outcomes
- Late lumen loss ranges from 0.22 ± 0.27 mm to 0.30 ± 0.54 mm.
- Rates of in-stent binary restenosis: 1.0% (RESOLUTE first-in-human), 4.2% (R-AC) and 9.2% (R-US).
- In-stent percent diameter stenosis: 10.1%.

Outcomes in complex patients
- 66.3% of patients in R-AC were complex; event rates were higher in both R-ZES and EES complex lesion groups but similar across stent types:
  - TLF: 8.9% for R-ZES and 9.7% for EES (p = 0.66);
  - TLR: 4.4% for R-ZES and 4.0% for EES (p = 0.80);
  - Death or MI: 5.6% for R-ZES and 7.4% for EES (p = 0.17);
  - Definite or probable ST (overall): 1.7% for R-ZES and 0.9% for EES (p = 0.26);
  - In-stent binary restenosis: 5.1% for R-ZES and EES (p = 1.00).
- Diabetes mellitus: 34.4% of patients in R-US – similar outcomes with TLF of 4.3% among patients with and without diabetes.
- Bifurcation lesions: R-ZES was safe and effective in treatment of bifurcation lesions in a registry of 180 patients. At 9 months the rate of freedom from major adverse coronary events was 97.8% and there were no ST events.
- Resolute Integrity ZES approved for use in EU, Israel, India, Columbia, Bosnia, Serbia and Macedonia; Investigational in USA, Canada, Australia and Japan.
- Endeavor Resolute ZES approved in Australia, EU, Israel, Latin America, South Africa and India; investigational in the USA, Canada and Japan.
Conclusion
The R-ZES has an innovative biocompatible polymer that allows for a sustained release of zotarolimus over a longer duration. Introduction of new DES polymer such as the R-ZES hold the promise of improved performance based on a unique combination of a biocompatible polymer, proven antiproliferative drug and a modern flexible stent design. This combination appears to be very effective and safe for both the average and the complex coronary lesion or patient. While results are available to 2 years of follow-up, ongoing follow-up to 5 years in this program will help define the long-term safety profile of this new stent.

Future perspective
As DES technology has progressed over the past decade, it has become clear that different drug, polymer and stent characteristics yield devices that are not interchangeable. While the success of early DES facilitated the treatment of a larger proportion of coronary lesions, allowing more patients to have relief of angina with a less invasive method than coronary artery bypass surgery, future device evaluation will require successive evaluation of novel devices in studies ranging from proof-of-principle to broadly inclusive designs, to observational, population-based studies. While at its core, PCI is a mechanical procedure, pharmaceutical and materials science has had a profound impact on the long-term success of these procedures. In order to allow continued innovation while preserving safety, creative device evaluation programs are essential.

References
Papers of special note have been highlighted as:
* of interest
18 Meredith IT, Worthley S, Whitbourn R et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from

Interv. Cardiol. (2012) 4(1) future science group


* Prospective observational study of the Resolute® zotarolimus-eluting stent compared with historical cohorts derived from the ENDEAVOR trials. Demonstrated safety and efficacy of the Resolute stent.


33 Meredith IT. TCT-238: 4-year clinical outcomes from the ENDEAVOR first-in-man trial. J. Am. Coll. Cardiol. 56(13), B55 (2010).


* Randomized clinical trial comparing the Resolute zotarolimus-eluting stent with the Xience V® everolimus-eluting stent in an inclusive cohort with more complex coronary disease. A 2-year follow-up on patient and stent-level end points demonstrated no difference between the two drug-eluting stent types.


